Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FISSION: XELOX + Fruquintinib + Sintilimab for Gastric Cancer Conversion Therapy
NCT06091423Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma. Primary endpoint: Progression Free Survival at 2 years. Started Oct 2023; status: recruiting.
02
Drugs
fruquintinibsintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06091423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091423.